Research programme: specifically-targeted antimicrobial peptides - C3J Therapeutics

Drug Profile

Research programme: specifically-targeted antimicrobial peptides - C3J Therapeutics

Alternative Names: C3CD-17; CD 17; MRSA STAMP; Sm STAMP

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Antibacterials; Peptide fragments
  • Mechanism of Action Microbiome modulators; Peptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium-difficile-infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 29 Nov 2016 C3 Jian is now called C3J Therapeutics
  • 17 Mar 2014 Preclinical development is ongoing in the US
  • 01 Jan 2007 Preclinical trials in Dental caries in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top